These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29340741)

  • 1. [Platelet inhibition in patients with coronary, cerebral and peripheral macroangiopathy : What, when and how long?].
    Halbach M; Baldus S
    Internist (Berl); 2018 Mar; 59(3):288-303. PubMed ID: 29340741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dual platelet aggregation inhibition in coronary artery stent implantation--what is evidence-based?].
    Baer FM; Erdmann E
    Dtsch Med Wochenschr; 2007 Jun; 132(23):1275-80. PubMed ID: 17541871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of 'on-treatment platelet reactivity' and relationship with cerebral micro-embolic signals in asymptomatic and symptomatic carotid stenosis.
    Kinsella JA; Oliver Tobin W; Tierney S; Feeley TM; Egan B; Coughlan T; Ronan Collins D; O'Neill D; Harbison JA; Doherty CP; Madhavan P; Moore DJ; O'Neill SM; Colgan MP; Saqqur M; Murphy RP; Moran N; Hamilton G; McCabe DJH
    J Neurol Sci; 2017 May; 376():133-139. PubMed ID: 28431600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
    Nakagawa I; Wada T; Park HS; Nishimura F; Yamada S; Nakagawa H; Kichikawa K; Nakase H
    J Vasc Surg; 2014 Mar; 59(3):761-7. PubMed ID: 24239116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
    Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW
    Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications.
    Goli RR; Contractor MM; Nathan A; Tuteja S; Kobayashi T; Giri J
    Curr Atheroscler Rep; 2017 Nov; 19(12):56. PubMed ID: 29103068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Optimal platelet inhibition after coronary stent implantation. Current status].
    Silber S; Hoffmeister HM; Bode C
    Herz; 2008 Jun; 33(4):244-53. PubMed ID: 18581073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ESC guidelines 2017 on peripheral arterial diseases : Summary of the most important recommendations and innovations].
    Espinola-Klein C
    Herz; 2017 Dec; 42(8):721-727. PubMed ID: 29143147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of aspirin and clopidogrel resistance in peripheral arterial disease.
    Guirgis M; Thompson P; Jansen S
    J Vasc Surg; 2017 Nov; 66(5):1576-1586. PubMed ID: 28893489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
    Zhou Y; Wang Y; Wu Y; Huang C; Yan H; Zhu W; Xu W; Zhang L; Zhu J
    BMC Cardiovasc Disord; 2017 Jun; 17(1):157. PubMed ID: 28619104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet pathophysiology, pharmacology, and function in coronary artery disease.
    Ibrahim H; Kleiman NS
    Coron Artery Dis; 2017 Nov; 28(7):614-623. PubMed ID: 28644213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
    Secemsky EA; Yeh RW; Kereiakes DJ; Cutlip DE; Steg PG; Massaro JM; Apruzzese PK; Mauri L;
    JACC Cardiovasc Interv; 2017 May; 10(9):942-954. PubMed ID: 28473118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet function testing in clinical diagnostics.
    Rechner AR
    Hamostaseologie; 2011 May; 31(2):79-87. PubMed ID: 21152677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.
    Geisler T; Kapp M; Göhring-Frischholz K; Daub K; Dösch C; Bigalke B; Langer H; Herdeg C; Gawaz M
    Heart; 2008 Jun; 94(6):743-7. PubMed ID: 17567647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New antiplatelet agents in the treatment of acute coronary syndromes.
    Sabouret P; Taiel-Sartral M
    Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial.
    Wong KS; Chen C; Fu J; Chang HM; Suwanwela NC; Huang YN; Han Z; Tan KS; Ratanakorn D; Chollate P; Zhao Y; Koh A; Hao Q; Markus HS;
    Lancet Neurol; 2010 May; 9(5):489-97. PubMed ID: 20335070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50).
    Bonaca MP; Gutierrez JA; Creager MA; Scirica BM; Olin J; Murphy SA; Braunwald E; Morrow DA
    Circulation; 2016 Mar; 133(10):997-1005. PubMed ID: 26826179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombogenesis and inhibition of platelet aggregation. Experimental aspects and future approaches.
    Badimon L; Badimon JJ; Fuster V
    Z Kardiol; 1990; 79 Suppl 3():133-45. PubMed ID: 2099036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.